MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
CTI BioPharma Corp. Operating Cash Flow 2011-2026 | CTIC
Annual Operating Cash Flow CTI BioPharma Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -81.2 M | -84.9 M | -42.2 M | -27.8 M | -39.8 M | -39.3 M | -76.7 M | -95.2 M | - | -35.8 M | -62.8 M | -60.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -27.8 M | -95.2 M | -58.7 M |
Quarterly Operating Cash Flow CTI BioPharma Corp.
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -31.1 M | - | -65.7 M | -50.2 M | -30 M | - | -54.9 M | -34.4 M | -16.8 M | - | -31.4 M | -20 M | -10.4 M | - | -16.3 M | -10.7 M | -3.46 M | - | -27.2 M | -15.1 M | -2.42 M | - | -28.8 M | -8.04 M | -8.7 M | - | -62.1 M | -48.9 M | - | - | - | - | - | - | - | - | - | - | - | - | -15.3 M | - | -45.8 M | -33.2 M | -19 M | - | -54.8 M | -38.7 M | -24.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.42 M | -65.7 M | -28.9 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.37 | -8.67 % | $ 350 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
-29.7 M | $ 1.65 | 6.11 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.43 | -2.69 % | $ 8.25 B |  Australia |
 |
Biogen
BIIB
|
2.88 B | $ 177.93 | -4.15 % | $ 25.9 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
180 M | $ 65.89 | -0.06 % | $ 8.81 B | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
5.96 B | $ 94.4 | 0.82 % | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 214.55 | 2.77 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
-74.1 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
15.2 B | $ 55.84 | 0.13 % | $ 113 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-342 M | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M |  Canada |
 |
Caladrius Biosciences
CLBS
|
-19.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 2.86 | - | $ 908 M |  Israel |
 |
Clearside Biomedical
CLSD
|
-18.1 M | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
-69.1 M | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
890 M | $ 106.88 | 4.6 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 4.18 | -1.65 % | $ 9.1 B | Israel |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Biosciences
CBIO
|
25.9 M | $ 11.09 | 1.0 % | $ 730 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Coherus BioSciences
CHRS
|
-175 M | $ 1.69 | 2.12 % | $ 159 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
213 M | $ 28.99 | -1.39 % | $ 1.4 B | USA |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 25.71 | 0.16 % | $ 1.66 M | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 4.24 | -0.47 % | $ 116 M | France |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 9.57 | -0.78 % | $ 1.55 B | Britain |